291 related articles for article (PubMed ID: 30304659)
1. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Agha ME; Monaghan SA; Swerdlow SH
N Engl J Med; 2018 Oct; 379(15):1479-1481. PubMed ID: 30304659
[No Abstract] [Full Text] [Related]
2. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature.
Beziat G; Ysebaert L; Gaudin C; Steinmeyer Z; Balardy L
Leuk Res; 2019 Oct; 85():106199. PubMed ID: 31415942
[No Abstract] [Full Text] [Related]
3. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
Gangat N; Konopleva M; Patnaik MM; Jabbour E; DiNardo C; Al-Kali A; Foran JM; Granroth GL; Olteanu H; Kadia T; Tefferi A; Pemmaraju N
Am J Hematol; 2022 Feb; 97(2):E62-E67. PubMed ID: 34807470
[No Abstract] [Full Text] [Related]
4. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.
Pemmaraju N
Curr Hematol Malig Rep; 2017 Dec; 12(6):510-512. PubMed ID: 29064022
[No Abstract] [Full Text] [Related]
5. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
6. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
7. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
Piccini M; Loscocco GG; Gianfaldoni G; Grieco P; Palmieri G; Pilerci S; Scappini B; Bosi A
Ann Hematol; 2020 Apr; 99(4):907-909. PubMed ID: 32030448
[No Abstract] [Full Text] [Related]
8. Blastic plasmacytoid dendritic cell neoplasm.
Munoz J; Rana J; Inamdar K; Nathanson D; Janakiraman N
Am J Hematol; 2012 Jul; 87(7):710. PubMed ID: 21953644
[No Abstract] [Full Text] [Related]
9. Blastic plasmacytoid dendritic cell neoplasm.
Lim D; Goodman H; Rademaker M; Lamont D; Yung A
Australas J Dermatol; 2013 May; 54(2):e43-5. PubMed ID: 23582004
[TBL] [Abstract][Full Text] [Related]
10. Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature.
Ruhangaza D; Mugabe MC; Kigonya CN; Lane AA; Morgan EA
J Glob Oncol; 2019 Jun; 5():1-6. PubMed ID: 31246550
[No Abstract] [Full Text] [Related]
11. [Blastic plasmacytoid dendritic cell neoplasm: two case reports].
Kaabar M; Lemaire P; Laribi K; Sandrini J; Pineau-Vincent F
Ann Biol Clin (Paris); 2015; 73(6):733-6. PubMed ID: 26553703
[TBL] [Abstract][Full Text] [Related]
12. Blastic plasmacytoid dendritic cell neoplasm in a young patient.
Li JN; Harker D; Vandergriff T; Dominguez A
Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560790
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.
Schwede M; Tan IT; Atibalentja DF; Dickman MM; Rieger KE; Mannis GN
Ann Hematol; 2020 Dec; 99(12):2973-2975. PubMed ID: 32968828
[No Abstract] [Full Text] [Related]
14. Two rare cases of blastic plasmacytoid dendritic cell neoplasm and a literature review.
Chu G; Verner E; Lee K; Painter V; Fletcher J; Curnow J
Leuk Lymphoma; 2014 Oct; 55(10):2405-7. PubMed ID: 24432892
[No Abstract] [Full Text] [Related]
15. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.
Mirgh S; Sharma A; Folbs B; Khushoo V; Kapoor J; Tejwani N; Ahmed R; Agrawal N; Choudhary PS; Mehta P; Bhurani D
Leuk Lymphoma; 2021 Dec; 62(12):3039-3042. PubMed ID: 34151693
[No Abstract] [Full Text] [Related]
17. [Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic study].
Sang W; Wang CF; Cheng YF; Liu X; Li XX; Gulinar A; Li JZ; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):326-30. PubMed ID: 22883672
[TBL] [Abstract][Full Text] [Related]
18. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
[TBL] [Abstract][Full Text] [Related]
19. Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate.
Sato S; Tanaka E; Tamai Y
Ann Hematol; 2019 Mar; 98(3):801-803. PubMed ID: 30652209
[No Abstract] [Full Text] [Related]
20. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]